Veru (VERU)
Develops oral candidates for obesity-related body composition and atherosclerotic inflammation.
Something off on this page? Send us feedback.
Develops enobosarm with semaglutide to preserve lean mass and physical function during obesity treatment, while advancing sabizabulin for vascular inflammation. It is a pre-commercial drug developer whose model depends on clinical success, regulatory approval, commercialization or partnering, and external financing.
Develops enobosarm, an oral selective androgen receptor modulator, for use with semaglutide in older people with obesity. The program focuses on preserving lean mass and physical function while increasing fat loss during treatment with a GLP-1 receptor agonist. Its active PLATEAU trial evaluates the combination at U.S. clinical sites, and initial labeling would be tied to the specific GLP-1 medicine studied.
Advances sabizabulin, an oral microtubule disruptor, as a potential broad anti-inflammatory treatment for atherosclerotic cardiovascular disease. Continuing operations have no retained marketed product after sales of the former female-condom, urology, and sexual-health businesses. Development, regulatory approval, commercialization or partnering, and external financing therefore underpin the business model. Chronic nonclinical toxicology is required before chronic sabizabulin dosing in atherosclerosis.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $23.9M · Total debt $2.7M · Total assets $37.0M · Shareholders' equity $28.4M
- Revenue
- $0
- Operating income
- −$7.7M
- Net income
- −$7.0M
No dividends on record.
| Institutions69 holders · as of Jun 30, 2026 | 17.78% | 3.03M shares | |
| Insiders2 holders · as of Aug 17, 2026 | 0.16% | 27.3K shares | |
| Otherremainder | 82.06% | 13.99M shares |
17.05M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Vanguard Capital Management LLCInstitution | 4.10% | 698,439 | 13Fas of Jun 30, 2026 |
Alyeska Investment Group, L.P.Institution | 1.40% | 238,556 | 13Fas of Jun 30, 2026 |
Oppenheimer & Co IncInstitution | 1.24% | 210,843 | 13Fas of Jun 30, 2026 |
BlackRock, Inc.Institution | 0.98% | 167,084 | 13Fas of Jun 30, 2026 |
Renaissance Technologies LLCInstitution | 0.96% | 164,450 | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 13, 2026 | K. Gary Barnette | officer: Chief Scientific Officer | +1,800 | $2.69 |
- Eli Lilly
Bimagrumab regimens target the same GLP-1 body-composition need.
- Regeneron
Trevogrumab plus semaglutide pursues similar lean-mass preservation.
- Scholar Rock
Apitegromab targets adjunctive obesity body composition.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Veru | $2.75 | +0.38% | $44.1M | — | — | — | −96.3% |
| Eli Lilly | $1,167.77 | +0.72% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Regeneron | $851.82 | −0.02% | $87.78B | 21.1 | 14.1 | 5.7 | +16.7% |
| Scholar Rock | $56.10 | +0.38% | $6.72B | — | — | — | — |
| Median | 30.0 | 21.2 | 9.7 | +32.2% |